TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain

Signal Transducer and Activator of Transcription (STAT) 3 emerged rapidly as a high-value target for treatment of cancer. However, small-molecule STAT3 inhibitors have been slow to enter the clinic due, in part, to serious adverse events (SAE), including lactic acidosis and peripheral neuropathy, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasembeli, Moses M., Singhmar, Pooja, Ma, Jiacheng, Edralin, Jules, Tang, Yongfu, Adams, Clydell, Heijnen, Cobi J., Kavelaars, Annemieke, Tweardy, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478865/
https://www.ncbi.nlm.nih.gov/pubmed/34274354
http://dx.doi.org/10.1016/j.bcp.2021.114688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478865/
https://www.ncbi.nlm.nih.gov/pubmed/34274354
http://dx.doi.org/10.1016/j.bcp.2021.114688

Ejemplares similares